Best tumor response and overall response rate (ORR) by disease site (n... | Download Table
ASH 2020: TRANSCEND-CLL-004 Study: Results of CAR-T Combination in R/R CLL or SLL
Abbreviations: CR, complete response; ORR, objective response rate; PR,... | Download Scientific Diagram
Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis - Ye - 2020 - Clinical Pharmacology & Therapeutics - Wiley Online
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
IKCS 2022: Real-world Clinical Outcomes of Patients with Metastatic Renal Cell Carcinoma Receiving Pembrolizumab + Axitinib vs Ipilimumab + Nivolumab
Neoadjuvant treatment of HER 2-positive breast cancer – pathological complete response ( pCR ) as a surrogate of long term outcomes in the context of regulatory guidelines and reimbursement recommendations | Semantic Scholar
A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer | Scientific Reports
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink
Objective response rate (A) and complete response rate (B) for the four... | Download Scientific Diagram
Clinical trial end points relevant to patients and society for rare cancers | Semantic Scholar
Observational Study Protocol CA209-7MA
How to Improve Survey Response Rates?
Investigator-assessed confirmed objective response rate (per RECIST),... | Download Scientific Diagram
Response rates Overall response rate and depth of response according to... | Download Scientific Diagram
Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy - ScienceDirect
Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer - touchONCOLOGY
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer | NEJM
ASH 2020: Results From the Phase 1/2 BRUIN Trial
For personal use only
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
I never lost hope” – One Man's Journey with Advanced Kidney Cancer
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma | NEJM
Frontiers | Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study
Best Overall Response Rate to Treatment | Download Table
